GlassScriptPhysician profile
Liseli Whitly James
NPI 1801317235
$1,327.83
in general payments reported to CMS, 2019-2025
20 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.05 · 2022: $315 · 2023: $436 · 2024: $317 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $225.36 | 2022-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $172.79 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $166.25 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $104.60 | 2023-2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.92 | 2022-2023 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $95.16 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $77.67 | 2023-2025 | |
| Exact Sciences Corporation | $74.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $59.01 | 2023-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $43.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.25 | 2024 | Eliquis |
| Sanofi Pasteur INC. | $25.61 | 2023 | |
| Inspire Medical Systems, INC. | $25.02 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $24.43 | 2025 | Recorlev |
| Ascendis Pharma Endocrinology INC | $20.06 | 2025 | Yorvipath |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $19.35 | 2021 | |
| Amgen INC. | $18.34 | 2024 | Otezla |
| Dynavax Technologies Corporation | $15.58 | 2023 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $14.87 | 2025 | Zoryve |
| Organon LLC | $10.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liseli James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.